Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Changing the Subject (Part 3): The “All-Cancer Trial”

This article was originally published in RPM Report

Executive Summary

Rather than try to “win” the drug pricing debate, the biopharma sector may be better served by coming up with new ideas to change the subject. We outlined our case for taking this approach – and the model for ideas that serve that goal – here. Now we offer our second proposal: a nationwide clinical trial open to every patient with a cancer diagnosis.

Advertisement

Related Content

Rethinking Oncology Development: Master Protocols May Shorten Time To Approval

Topics

Advertisement
UsernamePublicRestriction

Register